Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Atara Biotherapeutics (ATRA) EBT Margin (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed EBT Margin for 4 consecutive years, with 123.81% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT Margin fell 6925.0% year-over-year to 123.81%, compared with a TTM value of 71.56% through Sep 2025, up 20330.0%, and an annual FY2024 reading of 0.08%, up 322062.0% over the prior year.
  • EBT Margin was 123.81% for Q3 2025 at Atara Biotherapeutics, down from 13.6% in the prior quarter.
  • Across five years, EBT Margin topped out at 241.97% in Q4 2022 and bottomed at 8966.83% in Q2 2023.
  • Average EBT Margin over 4 years is 1633.71%, with a median of 91.24% recorded in 2024.
  • The sharpest move saw EBT Margin tumbled -148149bps in 2023, then soared 890032bps in 2024.
  • Year by year, EBT Margin stood at 241.97% in 2022, then plummeted by -612bps to 1239.52% in 2023, then soared by 118bps to 221.66% in 2024, then crashed by -156bps to 123.81% in 2025.
  • Business Quant data shows EBT Margin for ATRA at 123.81% in Q3 2025, 13.6% in Q2 2025, and 38.73% in Q1 2025.